ARTA
BPMC

A.R.T. Advisors’s Blueprint Medicines BPMC Stock Holding History

A.R.T. Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,177
Closed -$821K – 1349
2019
Q3 		$821K Buy
11,177
+7,600
+212% +$657K 0.04% 637
2019
Q2 		$337K Buy
+3,577
New +$295K 0.02% 907
2018
Q1 		– Sell
-11,177
Closed -$842K – 1505
2017
Q4 		$842K Buy
+11,177
New +$786K 0.04% 691
2017
Q1 		– Sell
-21,235
Closed -$595K – 1435
2016
Q4 		$595K Buy
+21,235
New +$640K 0.04% 673
2016
Q2 		– Sell
-10,791
Closed -$194K – 1370
2016
Q1 		$194K Sell
10,791
-13,700
-56% -$238K 0.01% 1177
2015
Q4 		$645K Buy
+24,491
New +$551K 0.03% 749

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

A.R.T. Advisors's BPMC Position: Q4 2019 in Review

A.R.T. Advisors sold out of Blueprint Medicines (BPMC) in Q4 2019, closing a stake of 11,177 shares — an estimated $821K sold.

A.R.T. Advisors first reported a position in BPMC in Q4 2015 and held it in 6 quarters. The position peaked at $842K in Q4 2017. 227 funds tracked by Wall St. Rank hold BPMC as of Q4 2019.

  • A.R.T. Advisors reported no remaining Blueprint Medicines position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 11,177 Blueprint Medicines shares in Q4 2019, an estimated $821K.
  • A.R.T. Advisors first reported a position in Blueprint Medicines in Q4 2015 and held it in 6 quarters.
  • A.R.T. Advisors's Blueprint Medicines position peaked at $842K in Q4 2017.
  • 227 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.